Genome Editing

Selected news for the healthcare topic - Genome Editing, collected since 10/2017. This healthcare topic shares news with CRISPR, Precision BioSciences, Intellia Therapeutics, Gene Therapy, Biotech and over a hundred others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
10/13/2021 LogicBio Therapeutics (NASDAQ:LOGC) Cut to Hold at Zacks Investment Research slatersentinel.com LogicBio Therapeutics (NASDAQ:LOGC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday, Zacks.com reports.According to Zacks, “LogicBio Therapeutics Inc. is a genome editing company. It focuses on developing medicines to treat rare diseases in patients with significant unmet medical needs. The company’s technology platform consists of GeneRide(TM). LogicBio Therapeutics Inc. is ...
10/13/2021 LogicBio Therapeutics (NASDAQ:LOGC) Cut to Hold at Zacks Investment Research rivertonroll.com LogicBio Therapeutics (NASDAQ:LOGC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “LogicBio Therapeutics Inc. is a genome editing company. It focuses on developing medicines to treat rare diseases in patients with significant unmet medical needs. The company’s technology platform consists of GeneRide(TM). LogicBio Therapeutics Inc. is ...
10/13/2021 WHO Guidelines on Human Genome Editing: Why Countries Need To Follow Them goodmenproject.com By Sheetal Soni , University of KwaZulu-NatalThe World Health Organisation (WHO) recently called on countries to stop any research that might lead to the birth of genetically edited human beings. The call was made with the release of the recommendations on human genome editing .Human genome editing has great potential. It can improve human health and medicine by making changes to DNA in cells to correct, introduce or delete ...
10/13/2021 APAC, Europe, America region to generate massive revenues for Genome Editing market by 2026 aeresearch.net The global Genome Editing market research offers valuable insight into the current state of the local and global markets. Similarly, the Genome Editing market study includes a variety of user-friendly presentations and diagrams, such as maps, pie charts, and graphs that depict the percentage of different service providers strategies used in the global market. A systematic evaluation, primary research interviews, and secondary research findings were used to construct this ...
10/13/2021 Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology Globe Newswire Collaboration combines Intellia’s proprietary genome editing technology platform with SparingVision’s significant ophthalmology expertise- Intellia will grant SparingVision exclusive rights to its leading in vivo CRISPR/Cas9 technology for the development of ocular therapies directed to three targets- Intellia will receive an equity stake in SparingVision and will have an option to obtain exclusive US commercialization rights for ocular therapies for two targets- SparingVision to host webcast to discuss ...
10/13/2021 Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology Globe Newswire Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology- Collaboration combines Intellia’s proprietary genome editing technology platform with SparingVision’s significant ophthalmology expertise- Intellia will grant SparingVision exclusive rights to its leading in vivo CRISPR/Cas9 technology for the development of ocular therapies directed to three targets- Intellia will receive an equity stake in SparingVision and will have an option to obtain ...
10/11/2021 Heritable human genome editing: Who decides? Science or society? BMJ ... also collaborative ambition. And finally, there are some for whom science is more like a marathon (perhaps, a marathon with hurdles and teammates). In my book Altered Inheritance: CRISPR and the ethics of human genome editing I suggest that science is like orienteering. It is an endurance sport; it can be an individual competition, a team relay or a marathon event: [T]he runners have to maneuver around obstacles while ...
10/10/2021 LogicBio Therapeutics (NASDAQ:LOGC) Lifted to Buy at Zacks Investment Research The Markets Daily ... to a buy rating in a research report sent to investors on Thursday morning, Zacks.com reports. The firm currently has $5.00 price objective on the stock. According to Zacks, “LogicBio Therapeutics Inc. is a genome editing company. It focuses on developing medicines to treat rare diseases in patients with significant unmet medical needs. The company’s technology platform consists of GeneRide(TM). LogicBio Therapeutics Inc. is based in Cambridge, Massachusetts ...
10/10/2021 LogicBio Therapeutics (NASDAQ:LOGC) Upgraded to Buy by Zacks Investment Research zolmax.com ... a hold rating to a buy rating in a research report report published on Thursday, Zacks.com reports. They currently have $5.00 price target on the stock. According to Zacks, “LogicBio Therapeutics Inc. is a genome editing company. It focuses on developing medicines to treat rare diseases in patients with significant unmet medical needs. The company’s technology platform consists of GeneRide(TM). LogicBio Therapeutics Inc. is based in Cambridge, Massachusetts ...
10/9/2021 LogicBio Therapeutics (NASDAQ:LOGC) Rating Increased to Buy at Zacks Investment Research Mayfield Recorder ... a $5.00 target price on the stock. Zacks Investment Research ‘s target price would indicate a potential upside of 26.58% from the company’s previous close. According to Zacks, “LogicBio Therapeutics Inc. is a genome editing company. It focuses on developing medicines to treat rare diseases in patients with significant unmet medical needs. The company’s technology platform consists of GeneRide(TM). LogicBio Therapeutics Inc. is based in Cambridge, Massachusetts ...
10/8/2021 LogicBio Therapeutics (NASDAQ:LOGC) Raised to Buy at Zacks Investment Research rivertonroll.com ... a $5.00 price objective on the stock. Zacks Investment Research ‘s price objective would suggest a potential upside of 15.47% from the company’s previous close. According to Zacks, “LogicBio Therapeutics Inc. is a genome editing company. It focuses on developing medicines to treat rare diseases in patients with significant unmet medical needs. The company’s technology platform consists of GeneRide(TM). LogicBio Therapeutics Inc. is based in Cambridge, Massachusetts ...
10/8/2021 LogicBio Therapeutics (NASDAQ:LOGC) Upgraded at Zacks Investment Research - WKRB News wkrb13.com ... has a $5.00 target price on the stock. Zacks Investment Research ‘s price target suggests a potential upside of 15.47% from the company’s previous close.According to Zacks, “LogicBio Therapeutics Inc. is a genome editing company. It focuses on developing medicines to treat rare diseases in patients with significant unmet medical needs. The company’s technology platform consists of GeneRide(TM). LogicBio Therapeutics Inc. is based in Cambridge, Massachusetts ...
10/8/2021 LogicBio Therapeutics (NASDAQ:LOGC) Upgraded to Buy at Zacks Investment Research Dakota Financial News ... a buy rating in a research report sent to investors on Thursday morning, Zacks.com reports. Zacks Investment Research currently has $5.00 price objective on the stock. According to Zacks, “LogicBio Therapeutics Inc. is a genome editing company. It focuses on developing medicines to treat rare diseases in patients with significant unmet medical needs. The company’s technology platform consists of GeneRide(TM). LogicBio Therapeutics Inc. is based in Cambridge, Massachusetts ...
10/7/2021 Nobel Prize Gender Gap Widens as No Women Awarded for Science in 2021 Newsweek ... science award had been given solely to a team of women since the inception of the prize in 1901. Emmanuelle Charpentier and Jennifer A. Doudna claimed the chemistry award for their development of a genome editing method.On the flip side, teams of men without women had shared the prize 172 times up to Wednesday's announcement. The Nobel Prize in chemistry this year went to Benjamin List and David MacMillan ...
10/7/2021 NTLA Stock: Why It Increased Today pulse2.com The stock price of Intellia Therapeutics Inc (NASDAQ: NTLA) – a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo – increased over 5% during intraday trading today. Investors have been responding positively to the company recently reporting the authorization of its Clinical Trial Application (CTA) by the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) to ...
10/7/2021 Genome Editing Industry Supply Chain Analysis, Growth Opportunities, Top Companies, Revenue Growth and Business Development Report by 2027 Wordpress.com Increasing genomic research across the globe coupled with high incidence of target diseases is expected to stimulate market growth The global Genome Editing market size is expected to reach USD 15.09 Billion by 2028 at a CAGR of 14.8%, according to the latest report by Reports and Data. Genome editing refers to a genetic engineering method used for insertion, deletion, or modification in the genome of any organism. Genome editing ...
10/6/2021 Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema Globe Newswire NTLA-2002 is the first single-dose genome editing therapeutic candidate designed to prevent attacks in people living with HAE to enter clinical study - NTLA-2002 is Intellia’s second in vivo CRISPR genome editing therapeutic candidate; program to leverage platform insights gained from ongoing development of NTLA-2001 for transthyretin (ATTR) amyloidosis - On track to initiate patient enrollment by year-end CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Intellia ...
10/6/2021 Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema firstwordpharma.com CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology bothin vivoandex vivo, today announced the authorization of its Clinical Trial Application (CTA) by the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) to initiate a Phase 1/2 study evaluating NTLA-2002 for the treatment of adults with hereditary angioedema (HAE ...
10/6/2021 Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema tmcnet.com TMCnet News [October 06, 2021] Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema- NTLA-2002 is the first single-dose genome editing therapeutic candidate designed to prevent attacks in people living with HAE to enter clinical study- NTLA-2002 is Intellia’s second in vivo CRISPR genome editing therapeutic candidate; program to leverage platform insights gained from ongoing development ...
10/6/2021 Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema tmcnet.com ... the Treatment of Hereditary Angioedema [October 06, 2021] Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema NTLA-2002 is the first single-dose genome editing therapeutic candidate designed to prevent attacks in people living with HAE to enter clinical study NTLA-2002 is Intellia’s second in vivo CRISPR genome editing therapeutic candidate; program to leverage platform insights gained ...